Amicus Therapeutics Inc (FOLD)

NASDAQ
12.830
-0.340(-2.58%)
After Hours
13.000
+0.170(+1.325%)
- Real-time Data
  • Volume:
    1,783,438
  • Day's Range:
    12.790 - 13.210
  • 52 wk Range:
    5.910 - 13.615

FOLD Overview

Prev. Close
13.17
Day's Range
12.79-13.21
Revenue
242.56M
Open
13.11
52 wk Range
5.91-13.615
EPS
-0.915
Volume
1,783,438
Market Cap
3.6B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,193,965
P/E Ratio
-14.11
Beta
0.852
1-Year Change
43.31%
Shares Outstanding
280,945,247
Next Earnings Date
Feb 23, 2023
What is your sentiment on Amicus?
or
Market is currently closed. Voting is open during market hours.

Amicus Therapeutics Inc News

Amicus Therapeutics Inc Analysis

Amicus Therapeutics Inc Company Profile

Amicus Therapeutics Inc Company Profile

Amicus Therapeutics, Inc. is a biotechnology company that is focused on discovering, developing, and delivering medicines for rare diseases. The Company's portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in patients with genetic variants. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. Pompe disease is a lysosomal disorder (LD) from deficiency in an enzyme, GAA. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221 (miglustat) that functions as an enzyme stabilizer.

Read More

Analyst Price Target

Average15.400 (+20.031% Upside)
High20.000
Low10.000
Price12.830
No. of Analysts10
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellBuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellStrong BuyStrong Buy
SummaryStrong SellStrong SellStrong SellStrong BuyStrong Buy
  • I wish i could be the CEO of the company. He sold his stocks accidentally on friday.
    0
    • I also sold at 8.8 after almost 2 years of bagholding. Now it's up
      0
    • Crim Jamernow breakout
      0
  • 04.11 = MA 50 crossed above the MA200
    0
    • monthly return= -25%
      0
      • Been spendin' most their livesLivin' in a shorters's paradise(4x)
        0
    • For 2021, the company expects total Galafold revenues of at least $300-$315 million, driven by continued operational growth and commercial execution across all major markets, including the United States, the EU, the U.K. and Japan.
      0
      • buying, crashing in 2 days, bagholding for a year to breakeven, crashing in 2 days, repeat
        0
    • with WH already worked, waiting here
      0
      • just sent to WSB the offer to try short squuze with WH and FOLD, let's see
        0
        • hahaah tnx
          0
      • why is it going down today?
        0
        • Avoid any recommendations (it's monkey business for big) use your brain and intuition, then you save your own money.
          0
          • O co chodzi, Wojciech?
            0
          • Miguel Angel Cuña I've been investing for more then four years from now. So, I followed, at the begining, recommendations given by so called experts. More then 60% of its were wrong or disapointed me. Now I know that my estimation of stock and intuition is no worse and some times better then experts from banks, etc. I try to follow Buffet's point of view in investing, of course, reading all opinions and recommendations given.
            0
        • I was right: *****and see you next year!
          1
          • Going south, 7, 5 or very bottom $2? Amicus=amicable or .... reverse.
            3